Flu and COVID-19 Can Awaken Dormant Breast Cancer Cells in the Lungs
New research shows respiratory viral infections trigger dormant metastatic breast cancer cells to proliferate, with human data confirming elevated mortality risk.
Summary
A landmark Nature study demonstrates that influenza and SARS-CoV-2 infections can awaken dormant disseminated breast cancer cells (DCCs) in the lungs of mice, causing rapid proliferation within days and massive metastatic expansion within two weeks. The mechanism is interleukin-6 (IL-6) dependent, and the infections impair normal anti-tumor immune responses. Crucially, these findings are supported by large-scale human observational data from the UK Biobank and Flatiron Health databases, showing that SARS-CoV-2 infection significantly increases cancer-related mortality and lung metastasis risk in cancer survivors. The study bridges infectious disease biology and cancer metastasis, suggesting viral infections may be an underappreciated trigger of late metastatic relapse.
Detailed Summary
Breast cancer kills primarily through metastatic disease, and a poorly understood phenomenon is that disseminated cancer cells (DCCs) can remain dormant in organs like the lung for years or even decades before suddenly proliferating into overt metastases. What triggers this 'awakening' has been a central question in cancer biology. This study in Nature proposes and rigorously tests the hypothesis that common respiratory viral infections—specifically influenza and SARS-CoV-2—are potent triggers of metastatic reactivation in the lung.
Using mouse models, the researchers established pulmonary breast cancer dormancy and then exposed animals to influenza or SARS-CoV-2 infection. Within days of infection, dormant DCCs lost their pro-dormancy phenotype and began proliferating. Within two weeks, there was a massive expansion of carcinoma cells into metastatic lesions. Both viral infections produced this effect, pointing to a shared inflammatory mechanism rather than virus-specific pathology. The key cytokine mediating this effect was identified as interleukin-6 (IL-6): blocking IL-6 signaling abrogated the infection-driven metastatic awakening. This implicates the well-known pulmonary inflammatory response to respiratory viruses as a direct driver of metastatic progression.
The immune landscape was also profoundly altered. The study found that DCCs suppress lung T cell activation, and that after influenza infection, CD4+ T cells paradoxically inhibit CD8+ T cell cytotoxic activity rather than supporting it, thereby sustaining the metastatic burden. This represents a form of immune subversion in which the cancer exploits the infection-driven immune response to evade destruction.
Critically, the mouse experimental findings were corroborated by two large human datasets. Analysis of cancer survivors in the UK Biobank (covering all cancer types) and Flatiron Health (specifically breast cancer patients) revealed that SARS-CoV-2 infection substantially increased the risk of cancer-related mortality and lung metastasis compared with uninfected cancer survivors. This epidemiological alignment strengthens the translational significance of the mechanistic findings enormously.
The implications are far-reaching. Seasonal influenza alone affects over one billion people annually, and COVID-19 has infected hundreds of millions. Cancer survivors represent a vulnerable population in whom respiratory viral infections may be silently accelerating metastatic progression. The study also offers a mechanistic rationale for aggressive vaccination and antiviral strategies in cancer survivors, and positions IL-6 pathway inhibition as a potential prophylactic or therapeutic intervention during viral respiratory illness in this group.
Key Findings
- Influenza and SARS-CoV-2 infections awaken dormant breast cancer cells in mouse lungs within days, causing massive metastatic expansion within two weeks.
- The metastatic awakening is IL-6 dependent; blocking IL-6 signaling prevents infection-driven DCC proliferation.
- Dormant cancer cells impair lung T cell activation; post-influenza CD4+ T cells inhibit CD8+ cytotoxicity, sustaining metastatic burden.
- UK Biobank and Flatiron Health analyses confirm SARS-CoV-2 infection significantly raises cancer mortality and lung metastasis risk in human cancer survivors.
- The effect occurs across two distinct respiratory viruses, suggesting it is driven by shared inflammatory responses rather than virus-specific mechanisms.
Methodology
Mouse models of pulmonary breast cancer dormancy were infected with influenza or SARS-CoV-2, and DCC proliferation and metastatic expansion were tracked. IL-6 dependence was tested with blocking experiments, and immune profiling assessed T cell dynamics. Human observational data from UK Biobank (all cancers) and Flatiron Health (breast cancer) were analyzed to assess the association between SARS-CoV-2 infection and cancer-related mortality or lung metastasis in cancer survivors.
Study Limitations
Mouse dormancy models may not fully replicate the complexity of human cancer dormancy, and causal inference from the observational human datasets is limited by potential confounding. The study focuses on breast cancer and lung metastasis; whether these mechanisms apply broadly to other cancers and organ sites requires further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.